Gabriela Morales-Rivera

Ms. Morales-Rivera’s recent client representations include the following:

General Corporate Counseling and Significant Transactions

• Relay Therapeutics in connection with:
  • its $63 million Series B financing
  • its $400 million Series C financing
  • its $460 million initial public offering
  • its collaboration and license agreement with Genentech for the development and commercialization of RLY-1971
  • its acquisition of ZebiAI for $85 million upfront
  • its $350 million follow-on offering
  • its $300 million “at-the-market” offering
• Forma Therapeutics in connection with:
  • its $100 million Series D financing
  • its $319.3 million initial public offering
  • its $275.8 million follow-on offering
  • its $200 million “at-the-market” offering
• Nimbus Therapeutics in connection with:
  • the $1.2 billion sale of its ACC inhibitor program to Gilead Bioscience
  • its multi-target strategic alliance with Celgene Corporation in immunology
  • its $65 million Series 2018 preferred stock financing
  • its $43 million Series B financing
  • its $60 million private financing round from life science investors RA Capital Management and BVF Partners L.P.
  • its $105 million private stock financing
• ElevateBio in connection with:
  • its $150 million Series A financing
  • its $193 million Series B financing
  • its $525 million Series C financing
• Akero Therapeutics in connection with:
  • its $65 million Series A financing
  • its $70 million Series B financing
  • its $105.8 million initial public offering
  • its $216.4 million follow-on public offering
• Accent Therapeutics $63.0 million Series B financing
• MoMa Therapeutics in its $86.0 million Series A financing
• ROME Therapeutics in connection with:
  • its $50 million Series A financing
  • its $77 million Series B financing
• Aptinyx in connection with:
  • its $65 million Series A financing
  • its $70 million Series B financing
  • its $117.8 million initial public offering
• Allovir in its $120 million Series B financing
• Cullinan Oncology in its:
  • $98.5 million Series B Financing
  • $131.2 million Series C Financing
  • $287.4 million initial public offering
• Exosome Diagnostics in connection with:
  • its $30 million Series C financing
  • its sale to Bio-Techne Corporation
• Kymera Therapeutics in connection with:
  • its $30 million Series A financing
  • its $65 million Series B financing
  • its research and development collaboration with Vertex Pharmaceuticals
  • its $200 million initial public offering
• Neon Therapeutics in connection with:
  • its $106 million Series B financing
  • its $100 million initial public offering
  • its $97 million sale to BioNTech
• Tango Therapeutics in connection with:
  • its $55 million Series A financing
  • its $60 million Series B financing
  • its $40 million equity financing

Public Company Representation and Capital Markets Transactions

• Adicet Bio, Inc. (formerly resTORbio, Inc.) in connection with:
  • its $97.8 million initial public offering
  • its $50 million follow-on offering
  • its $152 million follow-on offering and concurrent private placement
  • its $100.6 million follow-on offering
• Intellia Therapeutics in connection with:
  • its $150 million follow-on offering
  • its $115 million follow-on offering
  • its expanded licensing agreement with Regeneron Pharmaceuticals
  • its $600 million follow-on offering
• Vigil Neuroscience in its $91.1 million initial public offering 
• Talaris Therapeutics in its $150 million initial public offering
• Cabaletta Bio in its $75 million “at-the-market” offering
• Sage Therapeutics in its $575 million and $345 million follow-on offering
• Repligen Corp. in connection with:
  • its acquisition of TangenX Technology Corporation
  • its acquisition of Spectrum, Inc.
  • its $138 million follow-on offering